Clinical trial
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in…
NCT00035997 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00035997 |
|---|---|
| Title | Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis |
| Official title | An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zometa |
| Enrollment | 261 |
| Start date | Apr 1, 2002 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | May 8, 2002 |
| Last update posted | Nov 23, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: